He was talking about the biotechnology company ImmunityBio. EF Hutton analyst Jason Kolbert initiated coverage of ImmunityBio ...

Argus has a "buy" rating and $400 price target for UTHR stock, which closed at $362.33 on Jan. 7. Bio-Techne develops, manufactures and sells biotechnology reagents and instruments for the ...

reflects the changing nature of the biotech’s relationship with Vertex regarding Casgevy. The outlook may be improving as CRISPR’s stock has gained 30% from the lows it hit earlier this ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

The cyclical, high-risk, high-reward nature of the biotech industry is on full display in 2024. This industry is centered on using living organisms and bioprocesses for innovative drug development ...